UBS Raises Arm Holdings Price Target to $175
UBS analyst Timothy Arcuri raised the price target on Arm Holdings (NASDAQ: ARM) to $175.00 (from $170.00) while maintaining a Buy rating.
“At the ARM Everywhere event, the company introduced its new ARM-based CPU scaling to 136 cores and delivering up to ~2x better performance per watt versus x86.
While its absolute core count trails leading x86 alternatives, ARM believes its CPU to offer a compelling alternative for both agentic AI workloads and non-NVDA XPU server head nodes.
With orders from 8 customers already – led by META and OpenAI – traction is ahead of where we expected.
Based on the orders and visibility, ARM outlined a CPU ramp that does not strike us as particularly heroic and likely biased higher over time (~$1B CPU revenues by FY28 and ~$15B by FY31), implying ~15% market share when ramped.
From a financial perspective, ARM outlined a path to Revs/EPS of ~$7.8B/$3+ in FY28 and ~$25B/$9+ in FY31, which sits meaningfully above our prior estimates (and above our FY30 framework of ~$16B/$6).
We expect valuation to remain the main near-term pushback, with after-hours price still screening expensive at ~50x FY28 EPS; however, on FY31 EPS the multiple compresses to ~16x, which we think becomes increasingly compelling – particularly if incremental upside from potential SoftBank/OpenAI XPU-related royalties materializes and drives further estimate revisions.
Net, we are increasing our estimates and PT from $170 to $175, and reiterate our Buy rating.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.





